The Outcome of the Treatment of Hyperthyroidism with Radioiodine

Aim: Radioiodine treatment with iodine-131 (I-131) is a preferable treatment modality in the hyperthyroidism such as Graves’ disease, nodular and multinodular goitre. In this retrospective study, we aimed to report short-term results of the hyperthyroid patients admitted to our clinic. Material and Method: Two hundreds and seventy patients admitted to Meram Medical Faculty, Department of Nuclear Medicine from December 2001 to March 2005 was included the study. The diagnosis was Graves’ disease (GD) in 155 (57%), toxic adenoma (TA) in 46 (17%) and toxic multinodular goitre (TMNG) in 69 (26%). The dose administered to patients with GD was 5-28 mCi (mean 10,58 ± 3,43), TA was 6-25 mCi (mean 11,78 ± 3,93), and TMNG was 5-30 mCi (mean 12,13 ± 3,03). Results: After the mean 8,16 ± 7,40 months follow-up, 87 patients (32,2%) were hyperthyroid, 104 (38,5%) were euthyroid, and 79 (29,3%) were hypothyroid. The response of treatment in the long period follow-up was better than short period one. It was determined that the responded group has been followed-up the longer period than the non-responded group (9,10 ± 7,76 months vs 6,17 ± 6,15 months). Mean age of the responded group is 52,09 ± 12,56 years, the other is 56,16 ± 15,38. The difference is significant. Conclusion: In our opinion, the response rate of I-131 therapy would increase in the long term follow-up of hyperthyroid patients.